APO Research
Talk to an analyst

APO RESEARCH · REPORT

Amyotrophic Lateral Sclerosis (ALS)

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Amyotrophic Lateral Sclerosis (ALS) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

20 December 2025184 pages

Choose your research edition.

Industry ResearchAmyotrophic Lateral Sclerosis (ALS) Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Amyotrophic Lateral Sclerosis (ALS) Industry Growth and Trends Forecast to 203297 pages · $3,450 USDMarket StructureGlobal Amyotrophic Lateral Sclerosis (ALS) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Amyotrophic Lateral Sclerosis (ALS) Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Amyotrophic Lateral Sclerosis (ALS) Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Amyotrophic Lateral Sclerosis (ALS) market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Amyotrophic Lateral Sclerosis (ALS) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Amyotrophic Lateral Sclerosis (ALS) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Amyotrophic Lateral Sclerosis (ALS) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Amyotrophic Lateral Sclerosis (ALS) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Amyotrophic Lateral Sclerosis (ALS) include Sun Pharma, Sanofi, Lunan Pharma, Mylan Pharma, Mitsubishi Tanabe Pharma, Glemark Generics, Covis Pharma and Apotex, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Amyotrophic Lateral Sclerosis (ALS) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Amyotrophic Lateral Sclerosis (ALS) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Amyotrophic Lateral Sclerosis (ALS) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Amyotrophic Lateral Sclerosis (ALS) market size, projected growth trends, production technologies, key applications, and end-use industries.

Amyotrophic Lateral Sclerosis (ALS) Segment by Company

Sun Pharma

Sanofi

Lunan Pharma

Mylan Pharma

Mitsubishi Tanabe Pharma

Glemark Generics

Covis Pharma

Apotex

Amyotrophic Lateral Sclerosis (ALS) Segment by Type

Riluzole

Edaravone (Radicava)

Other

Amyotrophic Lateral Sclerosis (ALS) Segment by Application

Hospital

Drugs Store

Other

Amyotrophic Lateral Sclerosis (ALS) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Amyotrophic Lateral Sclerosis (ALS) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Amyotrophic Lateral Sclerosis (ALS) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Amyotrophic Lateral Sclerosis (ALS).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Amyotrophic Lateral Sclerosis (ALS) market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Amyotrophic Lateral Sclerosis (ALS) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Amyotrophic Lateral Sclerosis (ALS) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Amyotrophic Lateral Sclerosis (ALS) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Amyotrophic Lateral Sclerosis (ALS) Industry Trends Table 2. Amyotrophic Lateral Sclerosis (ALS) Industry Drivers Table 3. Amyotrophic Lateral Sclerosis (ALS) Industry Opportunities and Challenges Table 4. Amyotrophic Lateral Sclerosis (ALS) Industry Restraints Table 5. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Manufacturers Table 9. Global Amyotrophic Lateral Sclerosis (ALS) Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Amyotrophic Lateral Sclerosis (ALS) Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Amyotrophic Lateral Sclerosis (ALS) Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Amyotrophic Lateral Sclerosis (ALS) Manufacturers, Product Type & Application Table 13. Global Amyotrophic Lateral Sclerosis (ALS) Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Amyotrophic Lateral Sclerosis (ALS) by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Riluzole Table 17. Major Manufacturers of Edaravone (Radicava) Table 18. Major Manufacturers of Other Table 19. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2021-2026) & (k units) Table 21. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2027-2032) & (k units) Table 22. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Type (2021-2026) Table 23. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Type (2027-2032) Table 24. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 25. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2021-2026) & (k units) Table 26. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2027-2032) & (k units) Table 27. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Type (2021-2026) Table 28. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Hospital Table 30. Major Manufacturers of Drugs Store Table 31. Major Manufacturers of Other Table 32. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2021-2026) & (k units) Table 34. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2027-2032) & (k units) Table 35. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Application (2021-2026) Table 36. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Application (2027-2032) Table 37. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 38. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2021-2026) & (k units) Table 39. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2027-2032) & (k units) Table 40. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Application (2021-2026) Table 41. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Application (2027-2032) Table 42. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Region (2021-2026) & (k units) Table 44. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Region (2021-2026) Table 45. Global Amyotrophic Lateral Sclerosis (ALS) Sales Forecasted by Region (2027-2032) & (k units) Table 46. Global Amyotrophic Lateral Sclerosis (ALS) Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Amyotrophic Lateral Sclerosis (ALS) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 48. North America Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2021-2026) & (k units) Table 49. North America Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2027-2032) & (k units) Table 50. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 51. Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2021-2026) & (k units) Table 52. Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2027-2032) & (k units) Table 53. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2021-2026) & (k units) Table 55. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2027-2032) & (k units) Table 56. South America, Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 57. South America, Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2021-2026) & (k units) Table 58. South America, Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2027-2032) & (k units) Table 59. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Region (2021-2026) Table 63. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Region (2027-2032) Table 64. Sun Pharma Company Information Table 65. Sun Pharma Business Overview Table 66. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio Table 68. Sun Pharma Recent Development Table 69. Sanofi Company Information Table 70. Sanofi Business Overview Table 71. Sanofi Amyotrophic Lateral Sclerosis (ALS) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Sanofi Amyotrophic Lateral Sclerosis (ALS) Product Portfolio Table 73. Sanofi Recent Development Table 74. Lunan Pharma Company Information Table 75. Lunan Pharma Business Overview Table 76. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio Table 78. Lunan Pharma Recent Development Table 79. Mylan Pharma Company Information Table 80. Mylan Pharma Business Overview Table 81. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio Table 83. Mylan Pharma Recent Development Table 84. Mitsubishi Tanabe Pharma Company Information Table 85. Mitsubishi Tanabe Pharma Business Overview Table 86. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio Table 88. Mitsubishi Tanabe Pharma Recent Development Table 89. Glemark Generics Company Information Table 90. Glemark Generics Business Overview Table 91. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Product Portfolio Table 93. Glemark Generics Recent Development Table 94. Covis Pharma Company Information Table 95. Covis Pharma Business Overview Table 96. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio Table 98. Covis Pharma Recent Development Table 99. Apotex Company Information Table 100. Apotex Business Overview Table 101. Apotex Amyotrophic Lateral Sclerosis (ALS) Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Apotex Amyotrophic Lateral Sclerosis (ALS) Product Portfolio Table 103. Apotex Recent Development Table 104. Key Raw Materials Table 105. Raw Materials Key Suppliers Table 106. Amyotrophic Lateral Sclerosis (ALS) Distributors List Table 107. Amyotrophic Lateral Sclerosis (ALS) Customers List Table 108. Research Programs/Design for This Report Table 109. Authors List of This Report Table 110. Secondary Sources Table 111. Primary Sources List of Figures Figure 1. Amyotrophic Lateral Sclerosis (ALS) Product Image Figure 2. Global Amyotrophic Lateral Sclerosis (ALS) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Amyotrophic Lateral Sclerosis (ALS) Market Size (2021-2032) & (US$ Million) Figure 4. Global Amyotrophic Lateral Sclerosis (ALS) Sales (2021-2032) & (k units) Figure 5. Global Amyotrophic Lateral Sclerosis (ALS) Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Amyotrophic Lateral Sclerosis (ALS) Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Riluzole Image Figure 9. Edaravone (Radicava) Image Figure 10. Other Image Figure 11. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Type (2021-2032) Figure 14. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Drugs Store Image Figure 19. Other Image Figure 20. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Application (2021-2032) Figure 23. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Application (2021-2032) Figure 26. North America Amyotrophic Lateral Sclerosis (ALS) Sales and Growth Rate (2021-2032) & (k units) Figure 27. North America Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Country (2021-2032) Figure 28. U.S. Amyotrophic Lateral Sclerosis (ALS) Sales and Growth Rate (2021-2032) & (k units) Figure 29. Canada Amyotrophic Lateral Sclerosis (ALS) Sales and Growth Rate (2021-2032) & (k units) Figure 30. Mexico Amyotrophic Lateral Sclerosis (ALS) Sales and Growth Rate (2021-2032) & (k units) Figure 31. Europe Amyotrophic Lateral Sclerosis (ALS) Sales and Growth Rate (2021-2032) & (k units) Figure 32. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Country (2021-2032) Figure 33. Germany Amyotrophic Lateral Sclerosis (ALS) Sales and Growth Rate (2021-2032) & (k units) Figure 34. France Amyotrophic Lateral Sclerosis (ALS) Sales and Growth Rate (2021-2032) & (k units) Figure 35. U.K. Amyotrophic Lateral Sclerosis (ALS) Sales and Growth Rate (2021-2032) & (k units) Figure 36. Italy Amyotrophic Lateral Sclerosis (ALS) Sales and Growth Rate (2021-2032) & (k units) Figure 37. Netherlands Amyotrophic Lateral Sclerosis (ALS) Sales and Growth Rate (2021-2032) & (k units) Figure 38. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Sales and Growth Rate (2021-2032) & (k units) Figure 39. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Country (2021-2032) Figure 40. China Amyotrophic Lateral Sclerosis (ALS) Sales and Growth Rate (2021-2032) & (k units) Figure 41. Japan Amyotrophic Lateral Sclerosis (ALS) Sales and Growth Rate (2021-2032) & (k units) Figure 42. South Korea Amyotrophic Lateral Sclerosis (ALS) Sales and Growth Rate (2021-2032) & (k units) Figure 43. Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Sales and Growth Rate (2021-2032) & (k units) Figure 44. India Amyotrophic Lateral Sclerosis (ALS) Sales and Growth Rate (2021-2032) & (k units) Figure 45. Australia Amyotrophic Lateral Sclerosis (ALS) Sales and Growth Rate (2021-2032) & (k units) Figure 46. South America, Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Sales and Growth Rate (2021-2032) & (k units) Figure 47. South America, Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Country (2021-2032) Figure 48. Brazil Amyotrophic Lateral Sclerosis (ALS) Sales and Growth Rate (2021-2032) & (k units) Figure 49. South Africa Amyotrophic Lateral Sclerosis (ALS) Sales and Growth Rate (2021-2032) & (k units) Figure 50. Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Sales and Growth Rate (2021-2032) & (k units) Figure 51. Turkey Amyotrophic Lateral Sclerosis (ALS) Sales and Growth Rate (2021-2032) & (k units) Figure 52. Argentina Amyotrophic Lateral Sclerosis (ALS) Sales and Growth Rate (2021-2032) & (k units) Figure 53. UAE Amyotrophic Lateral Sclerosis (ALS) Sales and Growth Rate (2021-2032) & (k units) Figure 54. Egypt Amyotrophic Lateral Sclerosis (ALS) Sales and Growth Rate (2021-2032) & (k units) Figure 55. Chile Amyotrophic Lateral Sclerosis (ALS) Sales and Growth Rate (2021-2032) & (k units) Figure 56. Global Amyotrophic Lateral Sclerosis (ALS) Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Amyotrophic Lateral Sclerosis (ALS) Revenue (2021-2032) & (US$ Million) Figure 59. North America Amyotrophic Lateral Sclerosis (ALS) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue (2021-2032) & (US$ Million) Figure 61. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Amyotrophic Lateral Sclerosis (ALS) Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Amyotrophic Lateral Sclerosis (ALS) Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Riluzole
  • Edaravone (Radicava)
  • Other
Applications
  • Hospital
  • Drugs Store
  • Other
Companies covered
  • Sun Pharma
  • Sanofi
  • Lunan Pharma
  • Mylan Pharma
  • Mitsubishi Tanabe Pharma
  • Glemark Generics
  • Covis Pharma
  • Apotex

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Amyotrophic Lateral Sclerosis (ALS) Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Amyotrophic Lateral Sclerosis (ALS) Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Amyotrophic Lateral Sclerosis (ALS) Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Amyotrophic Lateral Sclerosis (ALS) Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Amyotrophic Lateral Sclerosis (ALS) Market Dynamics
  1. 2.1 Amyotrophic Lateral Sclerosis (ALS) Industry Trends
  2. 2.2 Amyotrophic Lateral Sclerosis (ALS) Industry Drivers
  3. 2.3 Amyotrophic Lateral Sclerosis (ALS) Industry Opportunities and Challenges
  4. 2.4 Amyotrophic Lateral Sclerosis (ALS) Industry Restraints
3 Amyotrophic Lateral Sclerosis (ALS) Market by Manufacturers
  1. 3.1 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Manufacturers (2021-2026)
  3. 3.3 Global Amyotrophic Lateral Sclerosis (ALS) Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Amyotrophic Lateral Sclerosis (ALS) Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Amyotrophic Lateral Sclerosis (ALS) Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Amyotrophic Lateral Sclerosis (ALS) Manufacturers, Product Type & Application
  7. 3.7 Global Amyotrophic Lateral Sclerosis (ALS) Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Amyotrophic Lateral Sclerosis (ALS) Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Amyotrophic Lateral Sclerosis (ALS) Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Amyotrophic Lateral Sclerosis (ALS) Tier 1, Tier 2, and Tier 3
4 Amyotrophic Lateral Sclerosis (ALS) Market by Type
  1. 4.1 Amyotrophic Lateral Sclerosis (ALS) Type Introduction
  2. 4.1.1 Riluzole
  3. 4.1.2 Edaravone (Radicava)
  4. 4.1.3 Other
  5. 4.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Type
  6. 4.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2021-2032)
  8. 4.2.3 Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Type (2021-2032)
  9. 4.3 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Type
  10. 4.3.1 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2021-2032)
  12. 4.3.3 Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Type (2021-2032)
5 Amyotrophic Lateral Sclerosis (ALS) Market by Application
  1. 5.1 Amyotrophic Lateral Sclerosis (ALS) Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Drugs Store
  4. 5.1.3 Other
  5. 5.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Application
  6. 5.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2021-2032)
  8. 5.2.3 Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Application (2021-2032)
  9. 5.3 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Application
  10. 5.3.1 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2021-2032)
  12. 5.3.3 Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Application (2021-2032)
6 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Region
  1. 6.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Region (2021-2032)
  3. 6.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Region (2021-2026)
  4. 6.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Amyotrophic Lateral Sclerosis (ALS) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Amyotrophic Lateral Sclerosis (ALS) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Region
  1. 7.1 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Region
  2. 7.1.1 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Region (2021-2026)
  4. 7.1.3 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Region (2027-2032)
  5. 7.1.4 Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Amyotrophic Lateral Sclerosis (ALS) Revenue (2021-2032)
  8. 7.2.2 North America Amyotrophic Lateral Sclerosis (ALS) Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Amyotrophic Lateral Sclerosis (ALS) Revenue (2021-2032)
  11. 7.3.2 Europe Amyotrophic Lateral Sclerosis (ALS) Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Sun Pharma
  2. 8.1.1 Sun Pharma Company Information
  3. 8.1.2 Sun Pharma Business Overview
  4. 8.1.3 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
  6. 8.1.5 Sun Pharma Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Amyotrophic Lateral Sclerosis (ALS) Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Lunan Pharma
  14. 8.3.1 Lunan Pharma Company Information
  15. 8.3.2 Lunan Pharma Business Overview
  16. 8.3.3 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
  18. 8.3.5 Lunan Pharma Recent Developments
  19. 8.4 Mylan Pharma
  20. 8.4.1 Mylan Pharma Company Information
  21. 8.4.2 Mylan Pharma Business Overview
  22. 8.4.3 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
  24. 8.4.5 Mylan Pharma Recent Developments
  25. 8.5 Mitsubishi Tanabe Pharma
  26. 8.5.1 Mitsubishi Tanabe Pharma Company Information
  27. 8.5.2 Mitsubishi Tanabe Pharma Business Overview
  28. 8.5.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
  30. 8.5.5 Mitsubishi Tanabe Pharma Recent Developments
  31. 8.6 Glemark Generics
  32. 8.6.1 Glemark Generics Company Information
  33. 8.6.2 Glemark Generics Business Overview
  34. 8.6.3 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
  36. 8.6.5 Glemark Generics Recent Developments
  37. 8.7 Covis Pharma
  38. 8.7.1 Covis Pharma Company Information
  39. 8.7.2 Covis Pharma Business Overview
  40. 8.7.3 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
  42. 8.7.5 Covis Pharma Recent Developments
  43. 8.8 Apotex
  44. 8.8.1 Apotex Company Information
  45. 8.8.2 Apotex Business Overview
  46. 8.8.3 Apotex Amyotrophic Lateral Sclerosis (ALS) Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Apotex Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
  48. 8.8.5 Apotex Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Amyotrophic Lateral Sclerosis (ALS) Value Chain Analysis
  2. 9.1.1 Amyotrophic Lateral Sclerosis (ALS) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Amyotrophic Lateral Sclerosis (ALS) Production Mode & Process
  6. 9.2 Amyotrophic Lateral Sclerosis (ALS) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Amyotrophic Lateral Sclerosis (ALS) Distributors
  9. 9.2.3 Amyotrophic Lateral Sclerosis (ALS) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst